公开(公告)号：US20220340527A1

公开(公告)日：2022-10-27

申请号：US17754118

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya OGURO ,  Makoto KAMATA ,  Shuhei IKEDA ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Shigemitsu MATSUMOTO ,  Hirotaka KAMITANI ,  Takaharu HIRAYAMA ,  Toshio TANAKA ,  Hiroshi BANNO ,  Nobuyuki TAKAKURA ,  Jinichi YONEMORI ,  Takuya FUJIMOTO

IPC: C07D211/04 ,  C07D237/08 ,  C07D239/26 ,  C07D405/02

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20180303841A1

公开(公告)日：2018-10-25

申请号：US15769295

申请日：2016-10-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahiro SUGIMOTO ,  Shinkichi SUZUKI ,  Hiroki SAKAMOTO ,  Masami YAMADA ,  Minoru NAKAMURA ,  Makoto KAMATA ,  Kenichiro SHIMOKAWA ,  Masaki OGINO ,  Eiji KIMURA ,  Masataka MURAKAMI ,  Takuto KOJIMA ,  Jinichi YONEMORI

IPC: A61K31/53 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28

CPC classification number: A61K31/53 ,  A61K31/517 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  C07D239/88 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10 ,  C07D405/14

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

公开(公告)号：US20180155333A1

公开(公告)日：2018-06-07

申请号：US15568644

申请日：2016-04-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taku KAMEI ,  Yasuyoshi ARIKAWA ,  Tomohiro OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Takashi MIKI ,  Jinichi YONEMORI ,  Yuya OGURO ,  Takahiro SUGIMOTO ,  Masaki SETO ,  Goushi NISHIDA ,  Makoto KAMATA ,  Hiroshi IMOTO

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/14 ,  C07D409/14 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

CPC classification number: C07D413/14 ,  A61K31/553 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14

Abstract: The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20170216255A1

公开(公告)日：2017-08-03

申请号：US15488002

申请日：2017-04-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: A61K31/4035 ,  A61K31/55 ,  A61K31/4439 ,  A61K31/325 ,  A61K31/4155 ,  A61K31/445 ,  A61K31/13

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20220089525A1

公开(公告)日：2022-03-24

申请号：US17310164

申请日：2020-01-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya OGURO ,  Makoto KAMATA ,  Satoshi MIKAMI ,  Shinji MORIMOTO ,  Sachie TAKASHIMA ,  Masaki DAINI ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Akinori TOITA ,  Florian PUENNER ,  Takahito KASAHARA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Fumie YAMAGUCHI ,  Minoru NAKAMURA ,  Takafumi YUKAWA

IPC: C07C255/60 ,  C07D213/82 ,  C07D401/12 ,  C07D409/12 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00

Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20210332053A1

公开(公告)日：2021-10-28

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya OGURO ,  Shigemitsu MATSUMOTO ,  Takeshi WAKABAYASHI ,  Norihito TOKUNAGA ,  Taku KAMEI ,  Mitsuhiro ITO ,  Satoshi MIKAMI ,  Masaki SETO ,  Shinji MORIMOTO ,  Shinji NAKAMURA ,  Sachie TAKASHIMA ,  Masataka MURAKAMI ,  Masaki DAINI ,  Makoto KAMATA ,  Minoru NAKAMURA ,  Yasufumi WADA ,  Hiroyuki KAKEI ,  Kazuaki TAKAMI ,  Taisuke TAWARAISHI ,  Jumpei AIDA ,  Kouichi IWANAGA ,  Satoshi YAMAMOTO

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20180162850A1

公开(公告)日：2018-06-14

申请号：US15735418

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Shinkichi SUZUKI ,  Hiroki SAKAMOTO ,  Masami YAMADA ,  Minoru NAKAMURA ,  Makoto KAMATA ,  Kenichiro SHIMOKAWA ,  Masaki OGINO ,  Eiji KIMURA ,  Masataka MURAKAMI ,  Jinichi YONEMORI ,  Takuto KOJIMA

IPC: C07D413/14 ,  C07D413/10 ,  C07D265/22 ,  C07D417/10 ,  C07F7/08 ,  C07D491/107 ,  A61P25/28

CPC classification number: C07D265/22 ,  A61P25/28 ,  C07B2200/07 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02 ,  C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US20180000780A1

公开(公告)日：2018-01-04

申请号：US15685800

申请日：2017-08-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: A61K31/4035 ,  A61K31/045 ,  A61K31/4406 ,  C07D471/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170081332A1

公开(公告)日：2017-03-23

申请号：US15311025

申请日：2015-05-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro SUGIMOTO ,  Kenichiro SHIMOKAWA ,  Takuto KOJIMA ,  Hiroki SAKAMOTO ,  Ikuo FUJIMORI ,  Minoru NAKAMURA ,  Masami YAMADA ,  Masataka MURAKAMI ,  Makoto KAMATA ,  Shinkichi SUZUKI

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.

公开(公告)号：US20130303553A1

公开(公告)日：2013-11-14

申请号：US13944370

申请日：2013-07-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiko TANIGUCHI ,  Masato YOSHIKAWA ,  Kasei MIURA ,  Tomoaki HASUI ,  Eiji HONDA ,  Keisuke IMAMURA ,  Makoto KAMATA ,  Haruhi KAMISAKI

IPC: C07D471/04 ,  C07D473/00 ,  C07D498/04

CPC classification number: A61K31/4353 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/522 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/14 ,  C07D473/00 ,  C07D473/28 ,  C07D487/04 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07D519/00 ,  C07F7/10

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症的药剂。 化合物由式（I）表示：其中符号在说明书中定义。